Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.
Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)
Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)
Safety and efficacy analysis of larotrectinib in TRK fusion–positive lung cancer, from WCLC 2021 as reported by Clinical Care Options (CCO)
Subgroup analysis of IMower010 trial evaluating adjuvant atezolizumab vs best supportive care in patients with resected stage IB-IIIA NSCLC after adjuvant chemotherapy, from WCLC 2021 as reported by Clinical Care Options (CCO)